Thiogenesis Therapeutics Corp. is a clinical-stage biopharmaceutical company developing next-generation sulfur-based therapeutics known as thiols, designed to treat inherited and acquired mitochondrial diseases. The company's lead candidate, TTI-0102, is a prodrug composed of cysteamine that addresses limitations of legacy thiol therapies by improving bioavailability, tolerability, and dosing schedules. TTI-0102 has demonstrated strong tolerability at high doses in early clinical testing. The company is advancing clinical trials across multiple disease indications, including mitochondrial encephalopathy lactic acidosis and stroke-like episodes (MELAS), Leigh syndrome, Rett syndrome, and pediatric metabolic dysfunction-associated steatohepatitis (MASH). Thiogenesis employs a capital-efficient regulatory strategy utilizing the 505(b)(2) pathway in the United States and plans to initiate Phase 3 trials in nephropathic cystinosis alongside ongoing Phase 2 studies in Europe and the United States. Headquartered in Toronto, Canada, the company focuses on addressing serious pediatric diseases with significant unmet medical needs.